DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK 1, down from NOK 9. The analyst sees the terms of the rights issue financing as "detrimental to the stock" and also struggles to identify substantial share price catalysts for the next 12- 18 months.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRRGF: